FeesSafety
Pluang+

Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Market News
22 Nov 2026, 00:15 WIB
The Motley Fool
View Source
Bullish
Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk lost its lead in the GLP-1 weight-loss shot market to Eli Lilly due to supply issues but has rebounded strongly with its new GLP-1 pill, which captured 80% of new oral treatment patients in Q3 2026. The company is shifting to a volume-driven model with lower prices, which pressured revenue but improved guidance shows stabilization. Despite competition and a 70% stock drop from highs, Novo Nordisk offers a high dividend yield of 4.5% and attractive valuation metrics, making it a compelling option for investors willing to accept some risk in a large, growing obesity treatment market.

Novo Nordisk shares trade at USD 37.82 on Pluang as of Nov 22, 2026 05:32 WIB, down 2.70% in one day. The stock offers a 4.75% dividend yield, attracting some investors despite a 62% sell order activity. Eli Lilly, Novo's competitor, trades at USD 1,347.11 with a smaller 0.30% daily decline and a much lower 0.51% dividend yield on Pluang.

More News (NVO)

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and notable improvements in health markers. This success could lead...

Company Fundamentals
Bullish
10 hours ago
Novo Nordisk offers a strong dividend yield and growth potential, driven by diabetes and weight-loss drugs.

Novo Nordisk offers a strong dividend yield and growth potential, driven by diabetes and weight-loss drugs.

Novo Nordisk stands out with a high dividend yield of 4.6%, growing steadily from $0.62 in 2019 to $1.85 per share in 2026, supported by a healthy payout ratio of 45%. The company's valuation appears attractive with a price-to-sales ratio of 3.5 and ...

Market News
Bullish
1 day ago
Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition

Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition

Novo Nordisk updated its 2026 free cash flow guidance to 60–70 billion DKK, supported by lower capital expenditure and a diversified product pipeline including the Wegovy pill. The company expects adjusted sales and operating profit to grow modestly ...

Analyst Insights
Bullish
3 days ago
Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.

Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.

Novo Nordisk has increased its free cash flow guidance to DKK 60–70 billion after reporting DKK 28.4 billion in Q3, with a gross margin improvement to 82.1%. The company's obesity drug is expanding internationally, and positive data on a lower-dose v...

Analyst Insights
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App